Upregulation of plasma CCL8 in mouse model of graft-vs-host disease
Related Experiment Video
Updated: Jun 24, 2026
Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease
Published on: March 17, 2020
Akinobu Ota1, Masaki Yamamoto, Tsukasa Hori
1Immuno-Biological Laboratories Co. Ltd., Gunma, Japan. do-ota@ibl-japan.co.jp
Objective:
Using a proteomic approach, we recently identified plasma CCL8 as a potential biomarker for diagnosis of graft-vs-host-disease (GVHD) in mice as well as humans. Because mass spectrometric analysis is only semi-quantitative, a quantitative method of measuring plasma CCL8 levels in mice is needed.
Materials And Methods:
We established an enzyme-linked immunosorbent assay for the quantitative measurement of CCL8 concentrations in mouse plasma.
Results:
Our newly established enzyme-linked immunosorbent assay revealed that the plasma CCL8 concentrations (mean +/- standard error; n=12) were 1287+/-55.7 ng/mL and 1604+/-110.8 ng/mL on days 7 and 14 after allogeneic bone marrow transplantation (BMT), respectively, while the plasma concentrations was 316.6+/-16.3 ng/mL on day 7 after syngeneic BMT. A Western blotting analysis also showed a difference in the plasma CCL8 levels between the allogeneic and syngeneic BMT groups, as did clinical GVHD scores. Neither lipopolysaccharide nor poly(I:C) elevated the plasma CCL8 concentrations, although a dramatic increase in interleukin-6 was detected after both treatments.
Conclusion:
An elevated plasma CCL8 concentration may be a promising plasma marker for GVHD in mouse models.
